%0 Journal Article %A Veronika Müller %A Nesrin Mogulkoc %A Martina Šterclová %A Beata Zolnowska %A Vladimír Bartoš %A Martina Plačková %A Ladislav Lacina %A Robert Slivka %A Martina Doubková %A Marina Roksandić Milenkovic %A Radka Bittenglová %A Imrich Jonner %A Magdalena Martusewicz-Boros %A Monika Žurková %A Ilona Binková %A Małgorzata Sobiecka %A Richard Tyl %A Marzena Trzaska-Sobczak Marzena Trzaska-Sobczak %A Pawel Sliwinski %A Vladimíra Lošťáková %A Sebastian Majewski %A Pavlína Lisá %A Katarzyna Lewandowska %A Hana Šuldová %A Jasna Tekavec-Trkanje %A Amelia Szymanowska-Narloch %A Lenka Šišková %A Anikó Bohács %A Ján Plutinský %A Bohumil Matula %A Štefan Tóth %A František Petřík %A Bučeková Bučeková %A Jana Pšíkalová %A Miklós Zsiray %A Jaroslav Lněnička %A Vladimír Řihák %A Zsuzsanna Szalai %A Zoltan Baliko %A Štefan Laššán %A Pavlína Musilová %A Imre Lajko %A Tomáš Snížek %A Jan Anton %A Jiří Homolka %A Peter Palúch %A Róbert Vyšehradský %A Renata Králová %A Jan Kervitzer %A Maria Szilasi %A Jan Kus %A Dragana Jovanovic %A Marta Hájková %A Michal Svoboda %A Jana Strenková %A Martina Vašáková %A Daniel Doležal %T Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients? %D 2017 %R 10.1183/1393003.congress-2017.PA3821 %J European Respiratory Journal %P PA3821 %V 50 %N suppl 61 %X Key feature of IPF is decline in forced vital capacity (FVC) and CO diffusion (DLco), but data on clinical determinants of this change in patients who have established disease are scarce. For a given patient it is unknown if different natural histories represent distinct phenotypes of IPF or if geographic, ethnic or other factors might have influence on progression.The EMPIRE (European Multipartner IPF Registry) is a multicountry IPF register in the CEE region. Out of 1229 patients from the registry 324 with available data on FVC and DLco at inclusion and at 6 months rapid decliners (RD: FVC >10% or DLco >10% in 6 months) and controls (C) were included into the analysis. Clinical characteristics at inclusion were analyzed between groups to find clinical determinants of RD.Average age was 67,4±9.7 years, more males were affected than females (male:female 221:103) most patients had classic signs of UIP on HRCT. Most common comorbidity was hypertension (50.9%), coronary heart disease (20.5%), diabetes (20.1%) and hyperlipidaemia (20.1%). RD of FVC was present in 33.7%, while RD of DLco in 53.3% of patients. Comparison of RD and C patients for smoking status, dyspnoe severity, comorbidities, HRCT pattern, lung function parameters at inclusion, 6 minute walk distance or the presence of pulmonary hypertension did not show any difference between groups.The rate of change in FVC or DLco among IPF patients is highly variable, with 34-53 % of patients showing increased rates of decline in FVC and/or DLco. No clinical characteristics could be identified which can predict rapid decline using the data of EMPIRE registry. %U